Detection Evaluation of a Novel Blood-based DNA Methylation Assay in Early-stage Hepatocellular Carcinoma Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

4816 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-11-29

Study Completion Date

2023-04-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trail is a multi-center,prospective observational study aimed to detect early-stage Hepatocellular Carcinoma by a Novel Blood-based DNA Methylation Assay(named Genetron HCC Methylation PCR Kit ). The accuracy of the kit will also be evaluated . The trail will be enroll approximately 4816 participants, including participants with HCC or benign diseases, and high risk factors for liver cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

AssesSment of Early-deteCtion basEd oN liquiD Biopsy in Hepatobiliary Cancer Malignancies

NCT04835675

Hepatobiliary Malignancies

COMPLETED

HCC Screening Using DNA Methylation Changes in ctDNA

NCT03483922

Hepatocellular Carcinoma

COMPLETED

Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Hepatocellular Carcinoma Recurrence Surveillance

NCT06653062

Hepatocellular Carcinoma (HCC)

RECRUITING

Study to Assess the Feasibility in Bile cfDNA of Resectable Biliary Tract Carcinomas

NCT05783973

This Study Aims to Reveal the Effectiveness, Accuracy, and Feasibility in Bile

UNKNOWN

Clinical Study of Pan-cancer DNA Methylation Test in Plasma

NCT05685524

Cancer

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Diagnostic performance evaluation:

Alpha-fetoprotein (AFP), liver ultrasound (US), dynamic contrast enhanced MRI and the kit examination will be performed on high-risk participants of primary liver cancer.

For subjects with typical imaging findings of hepatocellular carcinoma but an intrahepatic nodule diameter of ≤2 cm, an imaging study will be added to the above.

According to the clinical diagnostic criteria of primary liver cancer, the diagnostic performance of the kit, liver ultrasound examination (US) combined with alpha fetoprotein (AFP) detection will be evaluated, and the sensitivity of the kit, the kit combined with AFP, the kit combined with AFP and US, AFP combined with US screening for primary liver cancer will be compared.

Test performance evaluation:

Plasma samples of patients with and without HCC diagnosed according to the clinical diagnostic criteria of primary HCC will be collected and examined simultaneously by the kit and high-throughput human methylation sequencing (NGS sequencing).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Have high risk factors for liver cancer such as HBV and/or HCV infection, alcoholic liver disease, non-alcoholic steatohepatitis, long-term consumption of food contaminated with aflatoxin, liver cirrhosis caused by various other reasons, and family history of liver cancer Wait;
2. I or my legal representative can read, understand and sign the informed consent;
3. Agree to provide blood samples, be able to receive imaging examinations and have good clinical compliance;
4. The complete clinical basic information includes: the patient's unique traceability number (ID number/outpatient clinic number/medical insurance card number), age, gender, etc.

1. Confirmed primary hepatocellular carcinoma or confirmed non-HCC;
2. I or my legal representative can read, understand and sign the informed consent;
3. Agree to provide blood samples and have good clinical compliance;
4. The basic clinical information is complete, including: the patient's unique traceability number (ID number/outpatient clinic number/medical insurance card number), age, gender, imaging and/or pathological diagnosis results (for patients with primary liver cancer), imaging examination confirmed non-identical Liver cancer (non-HCC patients).

Exclusion Criteria

1. pregnant women;
2. Have received an organ transplant;
3. Diagnosed with other tumors;
4. The investigators judged that they were not eligible for inclusion.

Test performance evaluation:

1. pregnant women;
2. Have received an organ transplant;
3. Non-HCC patients diagnosed with other tumors;
4. Patients with primary hepatocellular carcinoma combined with other tumors;
5. The investigator judges that they are not eligible for inclusion.

Eligible Sex

Accepts Healthy Volunteers

No